SCHEMBL730489

SCHEMBL730489

O=C(O)[C@H]1NCCC[C@H]1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 1.00
BLM P54132 1/20 1.00
KMT2A Q03164 1/20 1.00
SLC1A2 P43004 2/20 0.75
ARG1 P05089 5/20 0.50
SLC1A1 P43005 1/20 0.42
SLC6A1 P30531 2/20 0.39
SLC6A11 P48066 1/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A13 Q9NSD5 1/20 0.39
ARG2 P78540 1/20 0.38
DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730490 1.00 MEN1 (1.00) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL7354481 1.00 MEN1 (1.00) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL6342928 1.00 MEN1 (1.00) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL730491 1.00 MEN1 (1.00) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL6342925 1.00 MEN1 (1.00) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL28347967 0.98 MEN1 (0.96) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL28348164 0.98 MEN1 (0.96) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL17743431 0.98 MEN1 (0.96) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL3463284 0.86 SLC1A2 (1.00) MEN1BLMKMT2ASLC1A2ARG1
SCHEMBL2177035 0.86 SLC1A2 (1.00) MEN1BLMKMT2ASLC1A2ARG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288599-B1 WOUND PACKING MATERIAL COMPRISING CHEMOEFFECTOR CHEMOKIND INC (US) 2023-06-07 EP claimed
US-11273077-B2 Wound packing material comprising chemoeffector CHEMOKIND INC (US) 2022-03-15 US claimed
EP-3668524-A1 TARGETING 2 -1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS Board Of Regents, The University Of Texas System (US) 2020-06-24 EP claimed
US-20200181201-A1 TARGETING ALPHA2DELTA-1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-06-11 US claimed
WO-2019036511-A1 TARGETING α2δ-1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-02-21 WO claimed
WO-2015127558-A1 METHODS AND USES FOR INDUCING OR FACILITATING MICTURITION IN A PATIENT IN NEED THEREOF UNIVERSITé LAVAL (CA) 2015-09-03 WO claimed
EP-2403831-B1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLOÝ3,4-b¨PYRIDINE ITALIANA SINT SPA (IT) 2015-05-20 EP claimed
US-8053585-B2 Protecting group for carboxylic acids that can be photolyzed by visible light CORNELL RESEARCH FOUNDATION, INC. (US) 2011-11-08 US claimed
US-20110137036-A1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) 2011-06-09 US claimed
US-20070243519-A1 Protecting group for carboxylic acids that can be photolyzed by visible light CORNELL RESEARCH FOUNDATION, INC. (US) 2007-10-18 US claimed
US-5587509-A Caged caboxyl compounds and use thereof CORNELL RESEARCH FOUNDATION, INC. (US) 1996-12-24 US claimed
US-5430175-A Caged carboxyl compounds and use thereof CORNELL RESEARCH FOUNDATION, INC. (US) 1995-07-04 US claimed
WO-1995015305-A1 CAGED CARVOXYL COMPOUNDS AND THEIR USE IN CHEMICAL KINETIC INVESTIGATION OF NEUROTRANSMITTER RECEPTORS CORNELL RESEARCH FOUNDATION, INC. (US) 1995-06-08 WO claimed
US-12180251-B2 Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-12-31 US disclosed
US-20240409514-A1 METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS ETHISMOS RESEARCH, INC. (US) 2024-12-12 US disclosed
US-20240300931-A1 Composition and Methods for Treating Attention Deficit Disorders LIPPA ARNOLD STAN (US) 2024-09-12 US disclosed
US-4990504-A Modulate excitatory amino acid receptor system FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) 1991-02-05 US disclosed
US-4946839-A ALZHEIMER'S DISEASE FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) 1990-08-07 US disclosed
US-4925664-A Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function UNIVERSITY OF UTAH (US) 1990-05-15 US disclosed
EP-0299513-A1 Azetidine derivatives, compositions and their use FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) 1989-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409514-A1 METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS SLC18A2, SLC6A2, SLC18A3 MEN1 2473/4885BLM 4108/4885KMT2A 2302/4885
US-20110137036-A1 SYNTHESIS OF (4aS,7aS)-OCTAHYDRO-1H-PYRROLO[3,4-b]PYRIDINE PDXK, OXA1L, PDK4 MEN1 4493/4885BLM 2299/4885KMT2A 4545/4885
US-20070243519-A1 Protecting group for carboxylic acids that can be photolyzed by visible light CYBA, ALDH3A1, HCCS MEN1 3646/4885BLM 4254/4885KMT2A 3799/4885
US-20240300931-A1 Composition and Methods for Treating Attention Deficit Disorders GRIN2A, GRIN2C, NTRK2 MEN1 4824/4885BLM 2853/4885KMT2A 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.